Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Blood Advances|January 27, 2022
IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphomaSuraya Elfrink, Martin Ter Beest, Luuk Janssen, et al.
Blood|August 2, 2019
High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sitesSuraya Elfrink, Charlotte M de Winde, Michiel van den Brand, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 22, 2023
Detection of Second Primary Lymphoma in Late Diffuse Large B-cell Lymphoma RecurrencesMadeleine R Berendsen, Diede A G van Bladel, Eva Hesius, et al.
Blood Advances|August 23, 2021
Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disordersJames Peter Stewart, Jana Gazdova, Nikos Darzentas, et al.
The Lancet. Haematology|November 3, 2023
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trialMartine E D Chamuleau, Frank Stenner, Dana A Chitu, et al.
Blood|October 26, 2016
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphomaZijun Y Xu-Monette, Ling Li, John C Byrd, et al.
The Journal of Pathology|November 29, 2018
Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferationsAliki Xochelli, Vasilis Bikos, Eleftheria Polychronidou, et al.
Blood Advances|August 8, 2023
A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphomaDiede A G van Bladel, Wendy B C Stevens, Leonie I Kroeze, et al.
European Journal of Cancer (Oxford, England : 1990)|October 20, 2024
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapiesFleur A de Groot, Tim J A Dekker, Jeanette K Doorduijn, et al.
Pageof 5